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their decision. Results emphasize the importance of ongoing
education for families, the role of the family-physician rela-
tionship, and the value of psychosocial support throughout
the transplant process. Although the current study is limited
by a small convenience sample that may not be representa-
tive of the large sickle cell population (i.e., self-selection to
attend the symposium may indicate greater interest in
pursuing transplant), these ﬁndings provide important
insight into the complexity of family decisions about HSCT.216
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Duration of Pneumocystis pneumonia (PCP) prophylaxis
after allogeneic HSCT is not well deﬁned. Guidelines
recommend at least six months, and longer for patients on
immunosuppression. We report six cases of PCP that
happened late after allo-HSCT (median 36 months, range 19-
80). All had received peripheral blood HSCT: three from
matched sibling donors (MRD), and three from matched
unrelated donors (MUD) (the latter with alemtuzumab
conditioning). At the time of PCP, three patients (#3, #4, #5)
were not on immunosuppression and had no active graft
versus host disease (GVHD). Their mean CD4 T cell count was
569 (range 411-664). The other three had late-acute (#6,
post-DLI) or chronic (#1 and #2) GVHD. Only #1 was on
prednisone (< 0.5 mg/kg); #2 and #6 were on MMF alone.
Their mean CD4 T cell count was 210 (range 86-380). #1 and
#5 were on PCP prophylaxis (dapsone, atovaquone).
Clinical presentationwas atypical. Subacute fever without
shortness of breath (SOB) was most common. Patient #1 was
asymptomatic, with diffuse inﬁltrates found on restaging
chest CT. Only #2 presented with acute SOB and hypoxemia.Tabel 1
Patient #
Age, gender
1
46M
2
35M
3
51M
Disease DLBCL HD DLBCL
Months after
Tx at PCP
36 58 36
HSCT donor MUD (campath) MRD MUD (campa
aGVHD GI No GI, skin
cGVHD Mouth, upper GI,
eyes
Extensive No
GVHD Rx Prednisone,
topical
steroids
MMF, azithromycin,
montelukast
None
CD4 (334-1556) 86 380 411
PCP prophylaxis Dapsone No No
Presentation Asymptomatic Acute SOB cough Subacute fev
CT Diffuse reticular
and ground
glass opacity
Ground glass opacities,
focal consolidation in both
upper lobes, and RML
Diffuse multi
ground glass
reticular opa
in both lungs
BAL GMS+ GMS+ GMS+
DFA+ DFA+ DFA+
PCR+ PCR+ PCR+All patients had ground-glass opacities, but these were pat-
chy/multifocal (n¼4) rather than diffuse (n¼2). PCR was
more sensitive than DFA or GMS. Response to TMP/SMX (Â
steroids) was uniformly positive.
Conclusion: PCP may occur late after transplant, even in the
absence of immunosuppressive therapy, active GVHD or
CD4-T lymphopenia. Patchy ground-glass opacities and
nonspeciﬁc inﬁltrates are the common radiologic feature.
Post-transplant CD4 count does not seem to be useful to
predict PCP or the need for prophylaxis. It is possible that
a qualitative immune T cell defect accounts for late PCP.217
Palliative Care Intergration into an Acute Leukemia and
Bone Marrow Transplant Program
Amy Velasquez 1, Erin Winters 2. 1 BMT, University of Kansas
Hospital, Westwood, KS; 2 BMT, University of Kansas Hospital
Advancements in bonemarrow transplant (BMT) have led
to an increasing number of patients surviving both their
initial cancer diagnosis, and the aggressive treatment used to
cure the cancer. However for most patients, this cure comes
at a signiﬁcant cost. Complications from BMT and chemo-
therapy regimens lead to chronic conditions, which impact
both quality and quantity of life. Palliative care is not only for
dying patients; It provides support for symptom manage-
ment, emotional support, and advance care planning for any
patient and family member facing serious illness. Most
importantly, palliative care improves communication
between the primary physician and family members, and
assists with sometimes very difﬁcult life questions. Clinical
integration of two palliative care MD clinic sessions have
been embedded into the BMT clinic workﬂow in February
2012. The purpose is to measure outcome support for the
staff, patient and family members on an outpatient basis and
increase palliative care physician referrals from the Bone
Marrow Transplant program. In addition, a goal is to increase
patient/family and team planning for end of life care and to
decrease the number of hospital deaths among Bone marrow4
46M
5
55M
6
54M
MZL TCL CLL
19 80 27
th) MUD (campath) MRD MRD
No Skin Skin, liver post-DLI
No No No
None None MMF, topicals
631 664 164
No Atovaquone No
er Subacute fever Subacute fever;
cough
Subacute fever;
cough
focal
and
cities
.
Bilateral ground
glass inﬁltrates.
Multi focal nodular
and diffuse
inﬁltrates.
RLL consolidation and
patchy ground glass
opacities in RML
and LLL.
GMS- GMS- GMS-
DFA- DFA- DFA+
PCR+ PCR+ PCR+
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Blood and Marrow Transplant Program has undertaken
a Quality Improvement Retrospective Project utilizing Palli-
ative Care in the outpatient setting, to proactively address
these chronic issues. Retrospective analysis suggests imple-
mentation of early Palliative Care in this patient population
improves quality of life, while reducing costly in-patient, end
of life care.218
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Background: Hematopoietic Cell Transplantation (HCT) is
a potentially curative therapy for high risk malignancies but
remains limited by treatment-related toxicity. Pre-HCT
cardiopulmonary exercise testing and longitudinal post-HCT
patient-reported outcome (PRO) surveillance are new tech-
niques that may help to predict risk and tailor interventions
to improve long term outcomes.
Patients and Methods: We performed a feasibility study
enrolling 32 patients into three cohorts (10 autologous HCT
recipients, 11 full intensity allogeneic HCT recipients, and 11
reduced intensity allogeneic HCT recipients). Pre-transplant
physiological measurements included VO2peak assessment by
cycle ergometer and 6-minute walk testing (6MWT). PRO
measurements included daily and weekly symptom inven-
tories derived from the NCI's PRO-CTCAE, and weekly HRQOL
assessments using the NIH's PROMIS Global Health measure.
Spearman correlation coefﬁcients, Wilcoxon Signed Rank
tests, and univariable Cox regression models were used to
determine the associations of variables with each other and
with outcomes.
Results: Median age at the time of transplantation was 57.6
years. Eighty-one percent of patients had intermediate or
advanced disease and 41% had a high school education or
lower. Pre-deﬁned feasibility criteria for enrollment (>60%)
and data collection were achieved. Ninety-one percent of
patients completed VO2peak and 6MWT prior to HCT. Ninety-
four percent of patients opted to use the electronic mode of
survey assessments. Weekly symptom surveys were
completed in a median of 4.3 minutes, and weekly HRQOL
surveys were completed in a median of 3 minutes. Themedianweekly completion rate was 100% in all cohorts from
the start of conditioning through hospital discharge. VO2peak
was positively correlated with 6MWT (r¼0.65, P < .001) and
negatively correlated with months of prior chemotherapy
(r¼-0.43, P¼ .03), and was not correlated with age or HCT-CI.
A VO2peak >16mL/kg*min (N¼21/29) was associated with
a decreased risk of mortality after HCT (HR 0.11 (0.02-0.59),
P ¼ .001). Patients with VO2peak 16mL/kg*min had higher
overall symptom scores and worse physical and mental
HRQOL at baseline and throughout the period of observation
than patients with VO2peak > 16mL/kg*min. In general,
symptoms were correlated with physical and mental HRQOL.
Individual symptoms differed in frequency and severity by
cohort and by time point, in clinically expected ways.
Statistically signiﬁcant differences were seen when
comparing all three cohorts by overall symptom scores and
by physical and mental HRQOL.
Conclusions: Pre-HCT cardiopulmonary exercise testing and
post-HCT longitudinal PRO surveillance are feasible, mean-
ingful, and potentially prognostic. These techniques should
be explored further in larger studies.219
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Introduction: HCT survivors are at risk of elevated symptom
burden. We examined demographic and treatment factors
that might predict six long-term symptoms: cancer-related
distress, depression, insomnia, fatigue, pain, and physical
limitations.
Method: Four invitations to participate were sent by email to
HCT survivors on the BMT InfoNet listserve, a patient
resource and advocacy site. Eligibility criteria included >18
years old, more than two years post-HCT, without a recur-
rence or second cancer in the prior two years, without severe
depression, able to communicate in English, and with
internet and email access. Measures were the Cancer and
Treatment Related Distress scale, the Symptom Checklist-90-
R depression, the Insomnia Symptom Questionnaire, the
Fatigue Symptom Inventory, the Brief Pain Inventory, and the
Short Form-36 physical function scale. Standardized cutoffs
were used for each measure to determine if participants had
symptoms. A sum was computed for a potential range of
scores (0-6).
Results: Of 493 registered survivors, 386 (78%) were eligible.
Participants were from the U.S. (94%, N¼361) and 12 other
countries, treated at 136 centers, largely Caucasian and non-
Hispanic (95%), on average 9 years post-HCT (SD¼6, range
2-33); 70% received allogeneic HCT, 20% were receiving
treatment for chronic graft versus host disease (cGVHD).
Mean age was 54 (SD¼12, range 19-76). Participants with
elevated scores on at least one symptom comprised just over
half of the sample (57%) and 27% reported 3 or more symp-
toms (N¼105). The least commonly endorsed symptom was
